Mylan (NASDAQ: MYL)‘s stock had its “overweight” rating reaffirmed by analysts at JPMorgan Chase in a research report issued to clients and investors on Wednesday, ARN reports. They currently have a $38.00 price target on the stock. JPMorgan Chase’s target price suggests a potential upside of 27.22% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at JP Morgan Cazenove raised their price target on shares of Mylan from $33.00 to $34.00 in a research note to investors on Friday, May 3rd. They now have an “overweight” rating on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of Mylan to $32.00 in a research note to investors on Tuesday, April 2nd. They now have a “hold” rating on the stock. Finally, analysts at Sanford C. Bernstein downgraded shares of Mylan from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, March 25th.
Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $33.33.
Mylan (NASDAQ: MYL) traded up 0.13% on Wednesday, hitting $29.91. Mylan has a 52-week low of $20.21 and a 52-week high of $31.22. The stock’s 50-day moving average is currently $29.44. The company has a market cap of $11.398 billion and a price-to-earnings ratio of 19.95.
Mylan, Inc. develops and markets generics along with a number of proprietary drugs. The Company’s product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson’s disease, and a wound care product to treat diabetic foot ulcers.